Paragon Therapeutics, Inc.

This week marks two significant milestones for Spyre as we celebrate our one-year anniversary and announce the initiation of our first clinical trial evaluating SPY001, an investigational half-life extended anti-α4β7 monoclonal antibody, in healthy volunteers. We are proud of the hard work and dedication that were required to reach this stage and excited about our future with two additional programs expected to enter clinical studies in the next year. Together, we hope these investigational therapies will lead to a meaningful step forward in the treatment of IBD. Learn more: https://lnkd.in/gi-ebw4A #IBD

May 19 is #WorldIBDDay, and we’re raising awareness for the millions of people living with inflammatory bowel disease (IBD). Not only does IBD have severe physical impacts, but the disease can also be extremely isolating when those around you don’t understand the severity of your symptoms or how to provide support. Spyre is committed to researching and developing treatment options to improve the experience for all IBD patients. Hear from our experts Joshua R Friedman and Deanna Nguyen to learn more about IBD and what is needed in the treatment landscape. #IBDAwareness #IBD

We are pleased to announce we have initiated dosing in the Phase 2 trial of APG777 in patients with moderate-to-severe #atopicdermatitis. CEO Michael Henderson shares more about this exciting milestone for Apogee below. Full details here. https://lnkd.in/eax5brnn

We are thrilled to announce the first healthy volunteer participants have been dosed in the Phase 1 clinical trial of APG808, our novel half-life extended IL-4Rα antibody for the treatment of #COPD and other inflammatory diseases. We expect to report interim subcutaneous safety and pharmacokinetic data in the second half of this year. CEO Michael Henderson shares more below. https://lnkd.in/e3tQyXmD

Today, we announced an additional $180M private investment in public equity (“PIPE”) financing agreement to advance our clinical pipeline of investigational antibody therapeutics. We are thankful for the continued support from our various investment partners who believe in Spyre’s mission to transform the treatment of #IBD. Together, we are engineering for new heights in the treatment of IBD. The net proceeds from this PIPE financing, together with existing cash, cash equivalents, and marketable securities, will extend our cash runway to fund its operating plan well into 2027. Full details of today’s announcement are available here: https://lnkd.in/e_KNTv-q #publiccompany #biotech #antibodyengineering

A big thank you to Nasdaq for joining us to celebrate the closing of our upsized $483M follow-on financing, extending our cash runway into Q1 2028. At Apogee, we are dedicated to advancing our programs to transform the I&I space for patients with high unmet needs and refuse to stop at “good enough.”

Today we announced positive Phase 1 interim data from the first-in-human study of our lead program, APG777. Initial data show APG777 was well tolerated in healthy volunteers and initial PK data support potential best-in-class dosing of every 3 or 6 months. Based on these findings, we plan to accelerate our timelines again and initiate a Phase 2 clinical trial of APG777 in moderate-to-severe #atopicdermatitis in the first half of this year. Read more below. https://lnkd.in/eZrX_Uzh

Wow, what a day! If you missed it, the entire Spyre team, along with our family and friends, rang the opening bell this morning at Nasdaq. It was truly an unforgettable moment that represents what Spyre is about – blending a passion for science and a strong business model to positively impact patients’ lives. A full replay is available here: https://lnkd.in/eJz78vY Many thanks to everyone involved. #publiccompany #IPO #biotech #NasdaqListed

It's official! Tomorrow Spyre Therapeutics makes its debut on NASDAQ as "SYRE". Our commitment is to developing next generation therapeutics for people living with IBD, including ulcerative colitis (UC) and Crohn’s disease (CD). Follow up to keep up to date on our journey and visit our website: www.spyre.com    #biotech #immunology #crohnsdisease #ulcerativecolitis #$SYRE